Koers Diamyd Medical AB Swiss Exchange
Aandelen
SE0005162880
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
16/05 | Diamyd Medical AB (publ) geeft updates over de registrerende Fase 3 studie | CI |
12/04 | Mijlpaal in Diamyd® Fase 3 studie bereikt | CI |
Omzet 2024 * | 3 mln. 284K 266K | Omzet 2025 * | 3 mln. 284K 266K | Marktkapitalisatie | 1,41 mld. 133 mln. 124 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -133 mln. -12,61 mln. -11,77 mln. | Nettowinst (verlies) 2025 * | -165 mln. -15,64 mln. -14,61 mln. | EV/omzet 2024 * | 422 x |
Nettoliquiditeiten 2024 * | 139 mln. 13,18 mln. 12,3 mln. | Nettoliquiditeiten 2025 * | 30 mln. 2,84 mln. 2,66 mln. | EV/omzet 2025 * | 459 x |
K/w-verhouding 2024 * |
-10,6
x | K/w-verhouding 2025 * |
-8,55
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 63,2% |
Recentste transcriptie over Diamyd Medical AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 10-04-16 |
Founder | 83 | 01-01-96 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 83 | 01-01-96 | |
Director/Board Member | 63 | 01-01-12 | |
Director/Board Member | 52 | 28-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 112 mld. | |
+4,43% | 22,94 mld. | |
-9,86% | 17,02 mld. | |
-16,38% | 16,88 mld. | |
-39,94% | 16,87 mld. | |
+2,80% | 13,63 mld. | |
+27,39% | 11,61 mld. | |
+106,26% | 10,31 mld. |